Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 1990 Dec;37(3):253-60.
doi: 10.1016/0028-2243(90)90032-v.

Hormonal postcoital contraception with an ethinylestradiol-norgestrel combination and two danazol regimens

Affiliations
Comparative Study

Hormonal postcoital contraception with an ethinylestradiol-norgestrel combination and two danazol regimens

G Zuliani et al. Eur J Obstet Gynecol Reprod Biol. 1990 Dec.

Abstract

The ethinylestradiol-norgestrel combination (EE-NG) for postcoital contraception, as described by Yuzpe, has been shown to be an effective method but with frequent side effects. To overcome the problem of adverse effects a new approach using danazol was proposed, but the efficacy and acceptability of this treatment have not yet been tested in large studies. In a 5-year period at the AIECS Family Planning Centre in Milan we treated 2448 women requesting postcoital contraception using Yuzpe's regimen and two danazol regimens (800 mg/1200 mg). The patients' acceptability for danazol treatment was higher than for Yuzpe's regimen due to fewer, milder and shorter side effects. Nine pregnancies occurred in the EE-NG group (2.21%), 17 in the 800 mg group (1.71%) and 6 in the 1200 mg group (0.82%). Our study shows a statistically significant efficacy against expected pregnancy rates both with Yuzpe's regimen and with danazol. The 1200 mg danazol treatment seems to be more effective and can be considered a valid alternative to the EE-NG combination for hormonal postcoital contraception.

PIP: The ethinyl estradiol-norgestrel combination (EE-NG) for postcoital contraception as described by Yuzpe has been shown to be an effective method but with frequent side effects. To overcome the problem of adverse effects, a new approach using danazol was proposed, but the efficacy and acceptability of this treatment has not yet been put to the test in larger groups. In a 5-year period at the AIECS Family Planning Center in Milan, the authors treated 2448 women requesting postcoital contraceptives using Yuzpe's regimen and 2 danazol regimens (800 mg/1200 mg). The danazol treatment met with a greater measure of patient acceptability than did Yuzpe's regimen, due mainly to the smaller number of side effects. 9 pregnancies occurred in the EE-NG group (2.21%), 17 in the 800 mg group (1.71%), and 6 in the 1200 mg group (0.82%). This study shows a statistically significant efficacy against expected pregnancy rates, both with Yuzpe's regimen and with danazol. The 1200 mg danazol treatment seems to be more effective and can be considered a valid alternative to the EE-NG combination for hormonal postcoital contraception.

PubMed Disclaimer

Publication types

LinkOut - more resources